At Quibim, we develop AI algorithms for clinical practice. Our business model transforms imaging data into actionable predictions, collaborating with pharmaceutical companies to improve treatment selection and outcome prediction.

In the lifecycle of our products, scientific ideas become marketable solutions. Focusing on QP-Prostate^®, this solution aims to improve prostate cancer diagnosis by addressing the limitations of PSA tests and variability in image interpretation by radiologists. Our tool automates lesion detection* and prostate segmentation, providing accurate results that facilitate radiologists’ work.

In a preliminary study with Mass General Hospital, QP-Prostate^® demonstrated high sensitivity and specificity in detecting prostate cancer. Want to learn more about how this tool is becoming the perfect ally for professionals? Discover it in our last ECR intervention.

*In the US:  Lesion detection functionality is under clinical investigation and not available for sale.